Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?

References

• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.
   PubMed Web of Science ®Google Scholar
• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44:1195–1203.
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2163–2196.
   PubMed Web of Science ®Google Scholar
• Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17:149–160.
   PubMed Web of Science ®Google Scholar
• Koblan KS, Kent J, Hopkins SC, et al. A Non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382:1497–1506.
   PubMed Web of Science ®Google Scholar
• Kharawala S, Hastedt C, Podhorna J, et al. The relationship between cognition and functioning in schizophrenia: a semi-systematic review. Schizophr Res Cogn. 2022;27:100217.
   PubMedGoogle Scholar
• de Winter L, Couwenbergh C, van Weeghel J, et al. Changes in social functioning over the course of psychotic disorders-A meta-analysis. Schizophr Res. 2022;239:55–82.
   PubMedGoogle Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–962.
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939–951.
   PubMed Web of Science ®Google Scholar
• Faden J, Citrome L. Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment. Expert Opin Pharmacother. 2019;20:11–24.
   PubMed Web of Science ®Google Scholar
• Citrome L, McEvoy JP, Saklad SR. Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses. 2016;10(3):163–177.
   PubMedGoogle Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Nitta M, et al. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019;18:208–224.
   PubMed Web of Science ®Google Scholar
• Citrome L, McEvoy JP, Todtenkopf MS, et al. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatr Dis Treat. 2019;15:2559–2569.
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;17(3): CD006654.
   Google Scholar
• Johnsen E, Jørgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry. 2008;8:31.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Nakahara N, Fujikoshi S, et al. Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study. Pragmat Obs Res. 2015;6:39–46.
   PubMed Web of Science ®Google Scholar
• Citrome L, Kantrowitz JT. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? Expert Rev Neurother. 2009;9:1045–1058.
   PubMed Web of Science ®Google Scholar
• Pillinger T, Beck K, Gobjila C, et al. Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74:261–269.
   PubMed Web of Science ®Google Scholar
• Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64–77.
   PubMed Web of Science ®Google Scholar
• Lord CC, Wyler SC, Wan R, et al. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Invest. 2017;127:3402–3406.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71–93.
   PubMed Web of Science ®Google Scholar
• Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50:410–472.
   PubMed Web of Science ®Google Scholar
• Keating D, McWilliams S, Schneider I, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. 2017;7:e013881.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Krause M, Huhn M, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry. 2017;4:694–705.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Li C, Huhn M, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017;27:835–844.
   PubMed Web of Science ®Google Scholar
• McDonagh MS, Dana T, Selph S, et al. Treatments for adults with schizophrenia: a systematic review [Comparative Effectiveness Review No 198, AHRQ Publ No 17(18)-EHC031-EF]. In: Agency for healthcare research and quality. Rockville MD: Agency for Healthcare Research and Quality; October 2017.
   Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–1097.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–1087.
   PubMed Web of Science ®Google Scholar
• Lybalvi [package insert]. Waltham MA: Alkermes, Inc.; 2021.
   Google Scholar
• Citrome L. Out of the pipeline: olanzapine-samidorphan combination for schizophrenia or bipolar I disorder. Curr Psychiatry. 2022;21:35–40.
   Google Scholar
• Holtsman M, Fishman SM. Chapter 10 - Opioid Receptors. In: Benzon HT, Raja SN, Molloy RE, et al. editors. Essentials of Pain Medicine and Regional Anesthesia (Second Edition) [Internet]. Philadelphia: Churchill Livingstone; 2005 [cited 2022 Jan 28]. p. 87–93. Available from: https://www.sciencedirect.com/science/article/pii/B9780443066511500149.
   Google Scholar
• McDonald J, Lambert D. Opioid receptors. BJA Educ. 2015;15:219–224.
   Web of Science ®Google Scholar
• Carli M, Donnini S, Pellegrini C, et al. Opioid receptors beyond pain control: the role in cancer pathology and the debated importance of their pharmacological modulation. Pharmacol Res. 2020;159:104938.
   PubMed Web of Science ®Google Scholar
• Zaveri NT. Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: progress in Translation from Preclinical Research to Clinical Utility. J Med Chem. 2016;59:7011–7028.
   PubMed Web of Science ®Google Scholar
• Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. Neuropsychopharmacology. 2018;43:2514–2520.
   PubMed Web of Science ®Google Scholar
• Cunningham JI, Eyerman DJ, Todtenkopf MS, et al. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates. J Psychopharmacol. 2019;33:1303–1316.
   PubMed Web of Science ®Google Scholar
• Peng J, Sarkar S, Chang SL. Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug Alcohol Depend. 2012;124(3):223–228.
   PubMed Web of Science ®Google Scholar
• Mauck WD, Warner DO. Pain in infants, children, and adolescents, 2nd editionanesthesiology. Cancer. 2004;100(4):758.
   PubMedGoogle Scholar
• Wang S. Historical review: opiate addiction and opioid receptors. Cell Transplant. 2019;28:233–238.
   PubMed Web of Science ®Google Scholar
• Bodnar RJ. Endogenous opioids and feeding behavior: a 30-year historical perspective. Peptides. 2004;25:697–725.
   PubMed Web of Science ®Google Scholar
• Bodnar RJ. Endogenous opioids and feeding behavior: a decade of further progress (2004-2014). A Festschrift to Dr. Abba Kastin. Peptides. 2015;72:20–33.
   PubMed Web of Science ®Google Scholar
• Nogueiras R, Romero-Picó A, Vazquez MJ, et al. The opioid system and food intake: homeostatic and hedonic mechanisms. Obes Facts. 2012;5:196–207.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Essential psychopharmacology: neuroscientific basis and practical applications. Cambridge, United Kingdom; New York, NY: Cambridge University Press; 2021.
   Google Scholar
• MacDonald AF, Billington CJ, Levine AS. Effects of the opioid antagonist naltrexone on feeding induced by DAMGO in the ventral tegmental area and in the nucleus accumbens shell region in the rat. Am J Physiol Regul Integr Comp Physiol. 2003;285:R999–R1004.
   PubMed Web of Science ®Google Scholar
• Clegg DJ, Air EL, Woods SC, et al. Eating elicited by orexin-a, but not melanin-concentrating hormone, is opioid mediated. Endocrinology. 2002;143:2995–3000.
   PubMed Web of Science ®Google Scholar
• Romero-Picó A, Vázquez MJ, González-Touceda D, et al. Hypothalamic κ-opioid receptor modulates the orexigenic effect of ghrelin. Neuropsychopharmacology. 2013;38:1296–1307.
   PubMed Web of Science ®Google Scholar
• Shiraishi J-I, Yanagita K, Fujita M, et al. Micro-opioid receptor agonist diminishes POMC gene expression and anorexia by central insulin in neonatal chicks. Neurosci Lett. 2008;439:227–229.
   PubMed Web of Science ®Google Scholar
• Wand GS, Schumann H. Relationship between plasma adrenocorticotropin, hypothalamic opioid tone, and plasma leptin. J Clin Endocrinol Metab. 1998;83:2138–2142.
   PubMed Web of Science ®Google Scholar
• Kantonen T, Pekkarinen L, Karjalainen T, et al. Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB1 receptor availability. Int J Obes (Lond). 2021;(46):400–407.
   PubMed Web of Science ®Google Scholar
• Wentland MP, Lu Q, Lou R, et al. Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone. Bioorg Med Chem Lett. 2005;15:2107–2110.
   PubMed Web of Science ®Google Scholar
• Alkermes (2006 Oct 6th). Press release: alkermes and rensselaer polytechnic institute announce exclusive licensing agreement for novel opioid receptor compounds. https://investor.alkermes.com/news-releases/news-release-details/alkermes-and-rensselaer-polytechnic-institute-announce-exclusive
   Google Scholar
• Alkermes (2008,December 4th). Alkermes Initiates Clinical Trial for ALKS 33, a Novel Oral Molecule with Potential Benefits in Addiction and Other CNS Disorders. https://pipelinereview.com/index.php/2008120423797/Small-Molecules/Alkermes-Initiates-Clinical-Trial-for-ALKS-33-a-Novel-Oral-Molecule-with-Potential-Benefits-in-Addiction-and-Other-CNS-Disorders.html
   Google Scholar
• Alkermes (2009 Nov 17th). Alkermes Initiates Phase 2 Clinical Study of ALKS 33 for the Treatment of Alcohol Dependence. https://investor.alkermes.com/news-releases/news-release-details/alkermes-initiates-phase-2-clinical-study-alks-33-treatment
   Google Scholar
• Alkermes (2010 Oct 25th). Alkermes Announces Positive Results from Phase 1 Study of ALKS 33 in Combination with Buprenorphine for Treatment of Cocaine Addiction. URL: https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-positive-results-phase-1-study-alks-33
   Google Scholar
• Alkermes (2011 Jul 7th) Alkermes Announces Results from Phase 2 Study of ALKS 33 for Treatment of Binge Eating Disorder. https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-results-phase-2-study-alks-33-treatment-binge
   Google Scholar
• Alkermes (2014 Jul 30th). Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder. https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-initiation-forward-5-clinical-study-alks-5461
   Google Scholar
• Dinoff A, Lynch ST, Sekhri N, et al. A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression. J Affect Disord. 2020;271:91–99.
   PubMed Web of Science ®Google Scholar
• Alkermes. (2019 Feb 1st). Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application. URL: https://investor.alkermes.com/news-releases/news-release-details/alkermes-receives-complete-response-letter-us-food-and-drug
   Google Scholar
• Alkermes (2013 Jan 3rd). Alkermes expands CNS pipeline and announces positive results from phase 1 Study of ALKS 3831, a novel antipsychotic therapy for the treatment of schizophrenia. URL: https://investor.alkermes.com/news-releases/news-release-details/alkermes-expands-cns-pipeline-and-announces-positive-results
   Google Scholar
• Citrome L, Graham C, Simmons A, et al. An Evidence-Based Review of OLZ/SAM for treatment of adults with schizophrenia or bipolar i disorder. Neuropsychiatr Dis Treat. 2021;17:2885–2904.
   PubMed Web of Science ®Google Scholar
• Alkermes (2021 Jun 1st). Alkermes announces FDA approval of LYBALVI™ for the treatment of schizophrenia and bipolar i disorder. https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-fda-approval-lybalvitm-treatment
   Google Scholar
• Dwoskin LP. Preface Emerging targets and therapeutics in the treatment of psychostimulant abuse. Adv Pharmacol. 2014;69:xi–xiii.
   PubMedGoogle Scholar
• Tan L, Gajipara N, Zhou Y, et al. In vivo characterization of the opioid receptor binding profiles of samidorphan and naltrexone in rats: comparisons at clinically relevant concentrations. Biol Psychiatry. 2021;89:S384.
   Web of Science ®Google Scholar
• Clark SD, Abi-Dargham A. The role of dynorphin and the kappa opioid receptor in the symptomatology of schizophrenia: a review of the evidence. Biol Psychiatry. 2019;86:502–511.
   PubMed Web of Science ®Google Scholar
• Kumar V, Lu H, Hard M, et al. Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: absolute Bioavailability and the Effect of Food and Age. Drugs R D. 2019;19:277–287.
   PubMed Web of Science ®Google Scholar
• Sun L, McDonnell D, Liu J, et al. Effect of food on the pharmacokinetics of a combination of olanzapine and samidorphan. Clin Pharmacol Drug Dev. 2019;8:503–510.
   PubMed Web of Science ®Google Scholar
• Sun L, McDonnell D, von Moltke L. Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanzapine and samidorphan, in adult subjects with schizophrenia. Clin Ther. 2018;40:1845–1854.
   PubMed Web of Science ®Google Scholar
• Sun L, Yagoda S, Yao B, et al. Combination of olanzapine and samidorphan has no clinically significant effect on the pharmacokinetics of lithium or valproate. Clin Drug Investig. 2020;40:55–64.
   PubMed Web of Science ®Google Scholar
• Sun L, Barter Z, von Moltke L, et al. Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet. CPT Pharmacometrics Syst Pharmacol. 2021;10:1071–1080.
   PubMedGoogle Scholar
• Potkin SG, Kunovac J, Silverman BL, et al. Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 ENLIGHTEN-1 Study. J Clin Psychiatry. 2020;81:19m12769.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. Rev. In: Rockville, md: u.s. dept. of health, education, and welfare, public health service, alcohol, drug abuse, and mental health administration, national institute of mental health, psychopharmacology research branch, division of extramural research programs. Rockville, MD: National Institute of Mental Health. 1976;76–338.
   Google Scholar
• Yagoda S, Graham C, Simmons A, et al. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. CNS Spectr. 2021;26:383–392.
   PubMed Web of Science ®Google Scholar
• Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-Week phase 3 study. Am J Psychiatry. 2020;177:1168–1178.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Silverman BL, DiPetrillo L, et al. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: results from the ENLIGHTEN-2 long-term extension. Schizophr Res. 2021;232:45–53.
   PubMed Web of Science ®Google Scholar
• Martin WF, Correll CU, Weiden PJ, et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry. 2019;176:457–467.
   PubMed Web of Science ®Google Scholar
• Brunette MF, Correll CU, O’Malley SS, et al. Olanzapine Plus Samidorphan (ALKS 3831) in schizophrenia and comorbid alcohol use disorder: a phase 2, randomized clinical trial. J Clin Psychiatry. 2020;81:19m12786.
   PubMed Web of Science ®Google Scholar
• Sun L, Yagoda S, Xue H, et al. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: results from a phase 1 QT/QTc study. Prog Neuropsychopharmacol Biol Psychiatry. 2020;100:109881.
   PubMed Web of Science ®Google Scholar
• Swartz MS, Stroup TS, McEvoy JP, et al. What CATIE found: results from the schizophrenia trial. Psychiatr Serv. 2008;59:500–506.
   PubMed Web of Science ®Google Scholar
• Olanzapine [package insert]. Indianapolis: IN. Eli Lilly and Company; 2021.
   Google Scholar
• Citrome L, Stauffer VL, Chen L, et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol. 2009;29:278–283.
   PubMed Web of Science ®Google Scholar
• GoodRx, Inc. Olanzapine, https://www.goodrx.com/olanzapine (accessed 2021 Nov 23).
   Google Scholar
• GoodRx, Inc. Lybalvi, https://www.goodrx.com/lybalvi (accessed 2021 Nov 23).
   Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600–610.
   PubMed Web of Science ®Google Scholar
• Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73:199–210.
   PubMed Web of Science ®Google Scholar
• Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17:235–244.
   PubMed Web of Science ®Google Scholar
• Liu NH, Daumit GL, Dua T, et al. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry. 2017;16:30–40.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Moore SC, Jacobs EJ, et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc. 2014;89:335–345.
   PubMed Web of Science ®Google Scholar
• Klein S, Allison DB, Heymsfield SB, et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping america’s health: association for weight management and obesity prevention; naaso, the obesity society; the American society for nutrition; and the American diabetes association. Am J Clin Nutr. 2007;85:1197–1202.
   PubMed Web of Science ®Google Scholar
• García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016;36:355–371
   PubMed Web of Science ®Google Scholar
• Dayabandara M, Hanwella R, Ratnatunga S, et al. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231–2241.
   PubMed Web of Science ®Google Scholar
• Cooper SJ, Reynolds GP. With expert co-authors (in alphabetical order):, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30:717–748.
   PubMed Web of Science ®Google Scholar
• Alvarez-Jiménez M, Hetrick SE, González-Blanch C, et al. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193:101–107.
   PubMed Web of Science ®Google Scholar
• Bruins J, Jörg F, Bruggeman R, et al. The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis. PLoS One. 2014;9:e112276.
   PubMed Web of Science ®Google Scholar
• Siskind D, Gallagher E, Winckel K, et al. Does switching antipsychotics ameliorate weight gain in patients with severe mental illness? a systematic review and meta-analysis. Schizophr Bull. 2021;47:948–958.
   PubMed Web of Science ®Google Scholar
• Speyer H, Westergaard C, Albert N, et al. Reversibility of antipsychotic-induced weight gain: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:577919.
   PubMedGoogle Scholar
• Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28:392–400.
   PubMed Web of Science ®Google Scholar
• Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168:947–956.
   PubMed Web of Science ®Google Scholar
• Bak M, Drukker M, Cortenraad S, et al. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: a meta-analysis. PLoS One. 2021;16:e0244944.
   PubMed Web of Science ®Google Scholar
• Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998;6:47–53.
   PubMedGoogle Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–1174.
   PubMed Web of Science ®Google Scholar
• de Silva Va, Suraweera C, Ratnatunga SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16:341.
   PubMed Web of Science ®Google Scholar
• Correll CU, Sikich L, Reeves G, et al. Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry. 2020;19:69–80.
   PubMed Web of Science ®Google Scholar
• Tek C, Ratliff J, Reutenauer E, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept. J Clin Psychopharmacol. 2014;34:608–612.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Sy S, Maguire GA. How and when to treat the most common adverse effects of antipsychotics: expert review from research to clinical practice. Acta Psychiatr Scand. 2021;143:172–180.
   PubMed Web of Science ®Google Scholar
• Goh KK, Chen C-H, Lu M-L. Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials. Int J Psychiatry Clin Pract. 2019;23:14–32.
   PubMed Web of Science ®Google Scholar
• Mahmood S, Booker I, Huang J, et al. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol. 2013;33:90–94.
   PubMed Web of Science ®Google Scholar
• Topiramate [package insert]. Titusville NJ: Inc.; 2021. Janssen Pharmaceuticals.
   Google Scholar
• Hunt HJ, Donaldson K, Strem M, et al. Effect of miricorilant, a selective glucocorticoid receptor modulator, on olanzapine-associated weight gain in healthy subjects: a proof-of-concept study. J Clin Psychopharmacol. 2021;41:632–637.
   PubMed Web of Science ®Google Scholar
• Weizman S, Shelef A, Bloemhof Bris E, et al. A double-blind, placebo-controlled trial of bupropion add-on to olanzapine or risperidone in overweight individuals with schizophrenia. J Clin Psychopharmacol. 2021;41:629–631.
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Slooff CJ, Haddad PM, et al. Weight change by baseline BMI from three-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database. J Psychopharmacol. 2013;27:358–365.
   PubMed Web of Science ®Google Scholar
• Schoemaker J, Naber D, Vrijland P, et al. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43:138–146.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Citrome L, Cummings H, et al. Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine. CNS Spectr. 2022 Mar;3:1–43. Epub ahead of print
   Google Scholar